What development phase is Calcein in?

Calcein is FDA-approved (marketed).

What is the generic name of Calcein?

OFTASCEINE is the generic (nonproprietary) name of Calcein.

Last reviewed 2026-04-20 · How we verify

Calcein (OFTASCEINE)

FDA-approved active Small molecule Quality 0/100

Oftasceine (Calcein) is a marketed drug that operates by binding to and displacing calcium ions in cells, affecting various cellular processes. The key composition patent for Oftasceine is set to expire in 2028, providing a clear timeline for potential generic competition. Without specific revenue or primary indication data, the primary risk remains the patent expiry, which could significantly impact market exclusivity and sales.

At a glance

Generic name	OFTASCEINE
Drug class	oftasceine
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Calcein CI brief — competitive landscape report
Calcein updates RSS · CI watch RSS